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Abstract
IMPORTANCE Nitric oxide precursors, such as the amino acid L-arginine and the biguanide
antidiabetic drugmetformin, have been associated with metabolism andmuscle function in patients
with Duchennemuscular dystrophy (DMD). The treatment of DMD remains an unmetmedical need.
OBJECTIVE To evaluate the benefits and harms of a combination of L-citrulline andmetformin
treatment among patients with DMD.
DESIGN, SETTING, AND PARTICIPANTS A single-center randomized double-blind placebo-
controlled parallel-group clinical trial was conducted between December 12, 2013, andMarch 30,
2016, at the University Children’s Hospital Basel in Switzerland. A total of 47 ambulant male patients
aged 6.5 to 10 years with genetically confirmed DMDwere recruited locally and from the patient
registries of Switzerland, Germany, Austria, and France. Data were analyzed from April 6, 2016, to
September 5, 2019.
INTERVENTIONS Patients in the treatment group received 2500mg of L-citrulline and 250mg of
metformin (combination therapy) 3 times a day for 26 weeks compared with patients in the control
group, who received placebo.
MAINOUTCOMESANDMEASURES The primary end point was the change in transfer and standing
posture, as assessed by the first dimension of theMotor FunctionMeasure, version 32, frombaseline
to week 26. Secondary end points included assessments of timed function, quantitative muscle
force, biomarkers for muscle necrosis, and adverse events. The 2 prespecified subgroups comprised
patients whowere able towalk 350mormore in 6minutes (stable subgroup) and patients whowere
not able to walk 350m in 6minutes (unstable subgroup) at baseline.
RESULTS Among 49 ambulantmale childrenwith DMDwhowere screened for eligibility, 47 patients
with amean (SD) age of 8.2 (1.1) years were randomized to a treatment group receiving combination
therapy (n = 23) or a control group receiving placebo (n = 24), and 45 patients completed the study.
No significant differences between groups were found in the results of timed function and muscle
force tests for overall, proximal and axial, and distal motor function. Among patients receiving
combination therapy, the Motor FunctionMeasure first dimension subscore decrease was 5.5%
greater than that of patients receiving placebo (95% CI, −1.0% to 12.1%; P = .09). The administration
of combination therapy had significantly favorable effects on the first dimension subscore decrease
among the 29 patients in the stable subgroup (6.7%; 95% CI, 0.9%-12.6%; P = .03) but not among
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Key Points
Question Does treatment with
L-citrulline andmetformin combination
therapy reduce motor function decline
in ambulant patients with Duchenne
muscular dystrophy?
Findings In this randomized clinical trial
of 47 ambulant male children aged 6.5
to 10 years with Duchenne muscular
dystrophy, treatment with a
combination of L-citrulline and
metformin therapies provided a
clinically relevant but not statistically
significant reduction in motor function
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Abstract (continued)
the 15 patients in the unstable subgroup (3.9%; 95% CI, −13.2% to 20.9%; P = .63). Overall, the
treatment was well tolerated with only mild adverse effects.
CONCLUSIONS ANDRELEVANCE Treatment with combination therapy was not associated with an
overall reduction in motor function decline among ambulant patients with DMD; however, a
reduction in motor function decline was observed among the stable subgroup of patients treated
with combination therapy. The statistically nonsignificant difference of distal motor function in favor
of combination therapy and the reduced degeneration of muscle tissue appear to support the
treatment concept, but the studymay have lacked sufficient statistical power. Further research
exploring this treatment option with a greater number of patients is warranted.
TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT01995032
JAMA Network Open. 2019;2(10):e1914171. doi:10.1001/jamanetworkopen.2019.14171
Introduction
Duchennemuscular dystrophy (DMD) is an X-linked recessive disease that occurs in 1 of 3800 to
6000male births.1 The genetic mutation results in loss of sarcolemmal dystrophin. In addition,
altered neuronal nitric oxide (NO) synthase andmitochondrial dysfunction impair muscle function.2-5
Duchennemuscular dystrophy is characterized by the rapid and irreversible replacement of normal
skeletal muscle with connective and adipose tissue, leading to a loss of motor function and muscle
degeneration. Current therapeutic management remains supportive.6
Metformin, a well-established biguanide treatment for diabetes, improves glucose tolerance by
decreasing hepatic glucose production, thereby decreasing the intestinal absorption of glucose and
improving insulin sensitivity. Beneficial effects on dystrophic skeletal muscle inmdxmice (ie, mice
with anmdx allele mutation that is equivalent to the mutation in the human dystrophin gene, DMD,
which causes DMD) have been observed.7,8 Mantuano et al8 suggested that despite the observed
amelioration in muscle histopathology and ex vivo diaphragm force, no clear protective actions on
dystrophic muscle metabolism inmdxmice were observed. The lack of metabolic effects may have
been owing to the inability of metformin treatment alone to increase the low muscle levels of the
amino acids L-arginine and L-citrulline and the amino sulfonic acid taurine, supporting the therapeutic
combination of metformin with NO sources. The amino acid L-citrulline is largely converted to
L-arginine in the kidneys.9 The intake of L-citrulline in humans leads to higher peak L-arginine and NO
concentrations compared with equivalent L-arginine doses and the intake of L-arginine itself, and
single oral doses of up to 15 g of L-citrulline have been well tolerated by patients without adverse
effects (AEs).10 In addition, L-citrulline reduces muscle necrosis in patients with low protein
intake.11,12 It has been suggested that L-citrulline has protective effects onmuscle protein
metabolism, mediated through NO synthase.13 The significantly reducedmuscle content of NO
precursors found inmdxmice, combined with the partial response of dystrophic muscle to
metformin,8 supports the concept of a combined therapy consisting of metformin and an NO
precursor, such as L-citrulline, to modify NO levels andmitochondrial metabolism and thereby
ameliorate muscle function in patients with DMD. To our knowledge, no other clinical trial has
evaluated the treatment of patients with DMD using a combination of L-citrulline andmetformin
therapies. We aimed to evaluate the benefits and harms of treatment with combination therapy
among children with DMD in a randomized clinical trial.
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Methods
StudyDesign and Participants
We performed a single-center randomized (1:1 ratio) double-blind placebo-controlled parallel-group
study in an outpatient setting (Figure 1). Patients were enrolled from December 12, 2013, to
September 22, 2015, and were recruited during routine care visits at the pediatric outpatient clinic of
the University Children’s Hospital Basel in Switzerland, which is a secondary referral center for
pediatric neuromuscular diseases. We also screened the DMD patient registries of Switzerland,
Germany, Austria, and France for eligible patients. The clinical trial was conducted in accordance with
the Declaration of Helsinki14 and the Guideline for Good Clinical Practice,15 and it was approved by
the local ethics committee (the ethics committee of both Basel cantons) and the Swiss Agency for
Therapeutic Products (Swissmedic). We followed the guidelines of the European Medicines
Agency16,17 for the conduct and design of the study. The clinical trial was monitored by independent
organizations (the Clinical Trial Unit of University Hospital Basel and Kammermann Monitoring
Services GmBhZug) and followed the Consolidated Standards of Reporting Trials (CONSORT) guidelines.
The study protocol has been published previously,16,18 and the original protocol is available in
Supplement 1. All examinations were performed at the University Children’s Hospital Basel. Patients
and parents were informed about preclinical evidence, alternative treatments, and possible benefits
and harms associated with the study at the screening visit. Oral informed assent from all children and
written informed consent from all parents were obtained. Data were analyzed from April 6, 2016, to
September 5, 2019.
We included patients aged 6.5 to 10 years with genetically confirmed DMDwhowere able to
walk at least 150m in 6minutes and hadmoderate motor function (40%, as measured by the first
dimension [D1; pertaining to transfer and standing posture] of the Motor FunctionMeasure [MFM]
scale). Patients who received the combination therapy or their L-arginine metabolites within the last
3 months were excluded from participation to eliminate interfering effects. Also excluded were
patients who (1) had received an unstable corticosteroid treatment within the last 6months; (2) were
participants in other clinical trials; (3) had known intolerance or hypersensitivity to any study
treatment; (4) had other chronic diseases or clinically relevant limitations of renal, liver, or heart
function; or (5) had a diagnosis of cancer or suspected cancer. No additional eligibility criteria
were applied.
Figure 1. CONSORT FlowDiagram
49 Patients assessed for eligibility
47 Randomized
23 Randomized to receive L-citrulline/metformin treatment
23 Received L-citrulline/metformin treatment
24 Randomized to receive placebo
1 Did not start treatmenta
23 Received placebo
23 Completed the study 22 Completed the study
1 Discontinued treatment after week 13 because of
lack of efficacy
1 Did not start treatmenta
23 Included in intention-to-treat analysis
2 Could not perform Motor Function Measure at
week 26
21 Included in complete-case analysis for primary
outcome
24 Included in intention-to-treat analysis
22 Included in complete-case analysis for primary outcome
2 Excluded (did not meet inclusion criteria)
a Indicates the same patient.
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Interventions andOutcomes
Eligible patients were randomized in a 1:1 ratio to either the combination therapy group or the
placebo control group by an independent researcher using a computer-generated randomization list.
Children in the treatment group received 2500mg of L-citrulline (via powder in sachets dissolved in
water) and 250mg of metformin (via metformin hydrochloride tablets). Children in the control group
received placebo consisting of mannitol administered via matching powder and tablets. Treatment
was administered 3 times daily over 26 weeks. Returnedmedication was counted at follow-up visits.
No change in concomitant care or usual practice occurred during the study period.
The primary outcomewas the change in patients’ ambulation after 26 weeks of treatment, as
assessed by the D1 subscore (range, 0-39, with 0 indicating no standing and transfer function and 39
indicating normal motor function; the result is expressed as a percentage of themaximum possible
score) on the MFM-32 scale, which consists of 32 items that evaluate patients’ motor function in
lying, sitting, and standing positions; the MFM tool has been validated for use in children.19 The D1
items are associated with the loss of ambulation in children with DMD, and the scale effectively
represents short-term (ie, 3-month) changes in motor function.20
Secondary outcomes of the study were changes in the following parameters: (1) overall motor
function (measured by the total MFM score); (2) proximal and axial motor functions (measured by
the MFM D2 [second dimension] subscore); (3) distal motor function (measured by the MFM D3
[third dimension] subscore); (4) motor function related to the speed of movement (measured by
timed function tests); (5) 6-minute walking distance (6-MWD);21,22 (6) knee extension and elbow
flexion (assessed by handheld dynamometry and quantitativemuscle testing) as measures of muscle
force independent of muscle function and aspect; and (7) biomarkers of muscle necrosis in plasma
and urine. Biomarkers in plasma included creatine kinase and creatine-kinase-MB isoform, aspartate
aminotransferase, alanine aminotransferase, L-lactate dehydrogenase, gamma-glutamyl transferase,
bilirubin, alkaline phosphatase, and creatinine; biomarkers in urine included summated branch chain
amino acids, summated essential and nonessential amino acids, and changes in safety-related
laboratorymarkers (complete blood cell count, renal and liver function tests, and sodium, potassium,
chloride, calcium, and phosphate levels). The last 7 thighmuscle tissue changes detected through
magnetic resonance imaging (MRI), using fat fraction (FF) and transverse relaxation time (T2)–
weighted images, were evaluated.20,23,24 All MRI examinations were performed using a 3-T MRI
scanner (Siemens Healthcare) consisting of two 16-element body array coils and 1 spine coil. One
independent MRI technologist, who hadmore than 15 years of experience in the use of MRI
evaluations for research purposes, performed all examinations according to a prespecified protocol.
Localization assessments comprised a series of scout images taken in 3 orthogonal directions
and additional scout images taken parallel and orthogonal to the femur as well as through the hip and
knee joint space. A single axial volume halfway between the knee and hip joints was selected for
image acquisition, fromwhichmultiple sections were reconstructed. For each patient, regions of
interest were manually drawn over the thighmuscles depicted on the axial images, and care was
given to areas with chemical shift artifacts. The 3 regions of interest chosen for evaluation were the
knee extensors (quadriceps), knee flexors (hamstrings), and adductor muscle groups in both legs.
The MRI analyses at baseline and week 26 were performed blinded and after completion of the
clinical trial. The 2-point Dixonmethod was used, in which 2 images at identical positions were
acquired so that water and fat protons could be observed through in-phase and opposed-phase
imaging, respectively. A combination of these images yielded combined water and fat images.
Relative fat contentmapswere generated from the pixelwise FF, whichwas calculated by dividing the
fat content by the fat plus water content. The regions of interest were placed on themaps, and the
mean fat content was calculated for each muscle group. With the exception of MRI evaluations,
which were performed only at baseline and week 26, all other outcomes weremeasured at 13 and 26
weeks after randomization.
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Sample Size, Randomization, andMasking
The sample size estimation was based on findings from a pilot study of 5 patients with DMD18 and
data from a study by Vuillerot et al,25 which reported that the natural progression of DMD in children
older than 6 years was associated with an annual change in theMFMD1 subscore of −17.2%. Data
indicated an early acceleration of motor function followed by a deceleration of motor decline and a
loss of ambulation. To simplify, we assumed a consistent decline owing to the natural progression of
the disease.26 At least 21 patients per group were needed to detect whether treatment with
combination therapy reduced this motor function decline by at least 50% over 26weeks (ie, a −4.3%
change in ambulation in the treatment group vs a −8.6% change in the control group, as measured
by theMFMD1 scale), with a 2-sided significance of α = .05 and a power of 0.8. A dropout rate of 10%
was assumed, and a total of 47 patients were enrolled.16
Patients were randomly allocated to the treatment and control groups using an initial
unbalanced group of 5 patients and subsequent randomly permuted balanced groups of 2 or 4
patients.27 An independent pharmacist dispensed either active or placebo compounds using a
computer-generated randomization list. The L-citrulline powder andmatching placebo powder were
prepared in identical sachets and prepackaged in cardboard boxes; the metformin tablets and
matching placebo tablets were dispensed in identical bottles. The cardboard boxes and bottles were
consecutively numbered for each participant based on the randomization schedule. All study
personnel, including study coordinators, study nurses, physiotherapists, and investigators, as well as
participants, caregivers, and outcome assessors, were blinded to treatment allocation.
Statistical Analysis
The primary analyses were based on the intention-to-treat (ITT) principle; thus, the effects of
treatment with combination therapy were compared with placebo in all randomized patients for
whom a baseline measurement of the primary end point was available (the ITT population). The
primary and secondary end points were modeled through an analysis of covariance, using the
measurement at week 13 or week 26 as the dependent variable, the measurement at baseline as the
covariate, and the group allocation (treatment or control) as the independent variable. To impute
missing outcome values, we performedmultiple imputations (n = 9999) through chained equations
using predictive mean matching that incorporated all variables of the linear models underlying the
analysis of covariance.
Two subgroup analyses were conducted. The first aimed to explore potentially different
treatment effects among patients who were at different stages of the disease. The natural course of
motor development and decline in patients with DMD comprises an initial improvement in function,
then a stable plateau followed by a phase of consistent motor function decline. We evaluated
patients based on their ability to walk 350m ormore (stable subgroup) or less than 350m (unstable
subgroup) in 6minutes. The homogeneity of patients in the stable subgroup differed from that of
patients in the unstable subgroup.28-31 The rate of motor decline in patients able to walk 350m or
more was relatively constant, while themotor function of patients unable to walk 350m either
continued to improve (if they were very young and still gainingmotor function) or soon declined until
they lost the ability to ambulate freely. The same procedure used to analyze the primary and
secondary end points was used to analyze each subgroup. This subgroup analysis was prespecified
in the statistical analysis plan before the end of the clinical trial and the unblinding of the data.
An additional subgroup analysis was performed post hoc to evaluate patients who did and did
not receive corticosteroid treatment before randomization. This subgroup analysis was not
prespecified in the statistical analysis plan. Corticosteroid therapy is considered a standard treatment
in this patient population and has been associated with better outcomes; however, this treatment is
often refused by parents and patients owing to concerns about AEs. In this subgroup analysis, we
explored potential treatment interactions and addressed confounding variables that may have been
present owing to the unbalanced proportions of patients who received corticosteroids before study
treatment despite randomization.
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To assess the robustness of the results, sensitivity analyses were conducted for all of the
outcomes in the safety population (a subset of the ITT population that comprised all patients who
were randomized and received1 dose of combination therapy) and the complete-case population
(a subset of the safety population that comprised all patients who were included in the complete
follow-up analysis for the primary end point; eTable 1 in Supplement 2). In addition, we performed
sensitivity analyses using other methods, such as complete-case and last-observation-carried-
forward techniques, to address missing data. All computations were performedwith R, version 3.6.1
(R Foundation for Statistical Analysis). All statistical tests were 2-sided with a significance level of
α = .05.
Results
A total of 49 ambulant male patients aged 6.5 to 10 years with DMDwere screened between
December 12, 2013, andMarch 30, 2016. Of those, 47 patients with a mean (SD) age of 8.2 (1.1) years
were randomized to the combination therapy group (n = 23) or the placebo control group (n = 24);
45 patients completed the study, with no missing data. Of the 2 patients who did not complete the
study, 1 did not reach an MFM D1 subscore of 40%, and the other was unable to complete the MFM
evaluation or perform the 6-MWD. Baseline characteristics were comparable in the treatment and
control groups, with the exception of corticosteroid use (Table 1). In both groups, 2 patients had
begun corticosteroid treatment between 6 and 12months before randomization. Two patients in the
control group withdrew consent, 1 before initiating study treatment and 1 owing to a lack of
treatment efficacy after 13 weeks. Two patients in the treatment group sustained a bone fracture; 1
patient fractured his femur on the right side, whichmade it impossible to assess his motor function at
weeks 13 and 26, and the other patient fractured his tibia, which resulted in the inability to perform
the MFM D1 evaluation at week 26. The 45 remaining patients completed 26 weeks of follow-up to
assess the primary outcome and were included in the complete-case analysis, and all of the initial 47
patients were included in the ITT analysis (Figure 1).
Table 1. Demographic and Baseline Characteristics of Intention-to-Treat Population
Characteristic
Mean (SD)
Combination Therapy Group (n = 23) Placebo Group (n = 24)
Age, y 8.2 (1.2) 8.2 (1.0)
Weight, kg 27.5 (7.1) 27.4 (6.2)
Height, m 1.3 (0.1) 1.3 (0.1)
BMI 17.6 (3.4) 17.3 (2.7)
Corticosteroid treatment, No. (%) 12 (52.2) 21 (87.5)
Plasma, μmol/L
L-Citrullinea 19.6 (5.2) 19.1 (4.6)
L-Argininea 66.1 (24.0) 66.6 (17.1)
L-Ornithinea 80.4 (20.1) 73.4 (16.6)
MFM score, %
Total 79.5 (7.4) 78.8 (5.6)
D1 60.1 (11.9) 58.0 (10.9)
D2 95.7 (5.3) 95.6 (4.0)
D3 89.9 (9.0) 89.7 (8.6)
6-MWD, m 362.0 (94.7) 356.7 (55.3)
Supine uptime, s 10.1 (6.6) 10.4 (6.3)
10-m walk test, s 6.7 (2.2) 6.8 (1.5)
Strength, N 164.8 (71.6) 156.4 (51.8)
MRI of muscle groupsb
FF, % 27.7 (12.0) 26.3 (13.3)
T2, ms 47.5 (6.5) 46.5 (6.7)
Abbreviations: BMI, bodymass index (calculated as
weight in kilograms divided by height in meters
squared); combination therapy, L-citrulline and
metformin treatment; D1, first dimension of theMFM,
referring to transfer and standing posture; D2, second
dimension of the MFM, referring to proximal and axial
motor functions; D3, third dimension of theMFM,
referring to distal motor function; FF, fat fraction;
MFM, Motor FunctionMeasure; MRI, magnetic
resonance imaging; 6-MWD, 6-minute walking
distance; T2, transverse weighted relaxation time.
a Reference ranges for L-citrulline are 18 to 50 μmol/L;
for L-arginine, 38 to 98 μmol/L; and for L-ornithine,
24 to 64 μmol/L.
b Themuscle groups evaluated were knee extensors,
knee flexors, and abductors in both legs.
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The change of motor function, as measured by theMFMD1 scale, did not indicate a statistically
significant difference at 26 weeks among patients in the treatment group (−4.0%; 95% CI, −8.7%
to 0.7%) compared with those in the control group (−9.6%; 95% CI,−14.1% to −5.1%), with a mean
between-group difference of 5.5% (95% CI, −1.0% to 12.1%; P = .09; Table 2 and Figure 2). An
examination of the primary end point at week 13 (eTable 2 in Supplement 2) and week 26 (Table 2)
indicates that differences between the treatment and control groups increased over time (eFigure in
Supplement 2).
No significant differences were found in the overall, proximal and axial, or distal motor function
assessments, in the timed function tests, or in themuscle force evaluation after 26 weeks of
treatment (Table 2).
Muscle degeneration was significantly reduced in the treatment group compared with the
control group at 26 weeks, as indicated by smaller changes in the FFs and T2 weighted relaxation
times from baseline, which were measured through quantitative MRI (qMRI) of the muscle groups
(knee extensors, knee flexors, and abductors). Themean between-group difference in the FFs of all 3
muscle groups in both legs was −1.7% (95% CI, −3.3% to −0.1%; P = .04), and the mean between-
group difference in the T2 weighted relaxation times of all 3 muscle groups was −1.4 milliseconds
(95% CI, −2.5 to −0.3 milliseconds; P = .02; Table 2 and Figure 2).
There were no significant differences between the treatment group 23 patients at weeks 13 and
26 and control group 24 patients at weeks 13 and 26 in laboratory biomarkers indicative of muscle
necrosis (eTable 3 and eTable 4 in Supplement 2 include outcomes at week 26 and week 13,
respectively).
Table 2. Overall Results atWeek 26 in Intention-to-Treat Population
Outcome
Combination Therapy Group (n = 23) Placebo Group (n = 24) Between-Group Difference
Mean (SD)
Change From Baseline
to Week 26 (95% CI)
Mean (SD)
Change From Baseline
to Week 26 (95% CI) Difference (95% CI) P ValueBaseline Week 26 Baseline Week 26
MFM score, %
Total 79.5 (7.4) 80.1 (6.2) 0.2 (−2.2 to 2.7) 78.7 (5.5) 76.0 (7.2) −2.9 (−5.3 to −0.5) 3.1 (−0.3 to 6.5) 0.07
D1 60.1 (11.9) 57.5 (14.0) −4.0 (−8.7 to 0.7) 58.0 (10.8) 49.5 (14.1) −9.6 (−14.1 to −5.1) 5.5 (−1.0 to 12.1) 0.09
D2 95.7 (5.3) 97.0 (2.3) 1.3 (−0.0 to 2.6) 95.6 (4.0) 95.6 (3.7) −0.0 (−1.4 to 1.3) 1.3 (−0.5 to 3.2) 0.16
D3 89.9 (9.0) 93.0 (4.9) 2.8 (0.4 to 5.2) 89.7 (8.6) 91.3 (8.9) 1.9 (−0.3 to 4.2) 0.9 (−2.4 to 4.2) 0.6
Strength, N 164.8 (71.6) 171.3 (72.7) −0.8 (−14.0 to 12.4) 156.4 (51.8) 148.9 (61.5) −11.9 (−24.9 to 1.0) 11.1 (−7.4 to 29.6) 0.23
6-MWD, m 362.0 (94.7) 339.0 (102.3) −30.6 (−62.4 to 1.1) 356.7 (55.3) 330.8 (89.3) −30.3 (−62.2 to 1.6) 0.3 (−45.1 to 44.6) 0.99
10-m walk test,s 6.7 (2.2) 6.9 (2.2) 0.7 (−0.4 to 1.7) 6.8 (1.5) 7.9 (3.3) 1.5 (0.5 to 2.5) −0.8 (−2.3 to 0.6) 0.25
Supine uptime, s 10.1 (6.6) 11.7 (8.5) 2.3 (−1.8 to 6.5) 10.4 (6.2) 12.7 (10.6) 4.1 (−0.3 to 8.4) −1.7 (−7.7 to 4.3) 0.57
MRI of muscle
groupsa
FF, % 27.7 (12.0) 31.7 (13.2) 3.5 (2.4 to 4.6) 26.3 (13.3) 29.7 (15.1) 5.2 (4.0 to 6.3) −1.7 (−3.3 to −0.1) 0.04
T2, ms 47.5 (6.5) 49.5 (7.8) 1.9 (1.1 to 2.7) 46.5 (6.7) 48.6 (8.8) 3.3 (2.5 to 4.1) −1.4 (−2.5 to −0.3) 0.02
6-MWD at
baselineb
≥350 m 67.1 (9.2) 63.7 (9.8) −2.74 (−7.00 to 1.51) 60.7 (12.1) 52.3 (12.7) −9.5 (−13.4 to −5.6) 6.7 (0.9 to 12.6) 0.03
<350 m 51.0 (8.6) 47.4 (14.4) −4.86 (−16.4 to 6.8) 52.6 (4.5) 43.6 (16.1) −8.7 (−21.4 to 4.0) 3.9 (−13.2 to 20.9) 0.63
Corticosteroid
treatmentc
Yes 58.5 (10.8) 53.4 (13.2) −6.3 (−12.7 to 0.2) 58.5 (11.1) 50.9 (14.3) −8.70 (−13.6 to −3.8) 2.4 (−5.7 to 10.5) 0.55
No 61.8 (13.4) 62.1 (14.0) −0.4 (−8.6 to 7.8) 54.7 (9.7) 41.0 (11.2) −15.3 (−29.7 to −0.9) 14.8 (−2.3 to 32.0) 0.08
Abbreviations: Combination therapy, L-citrulline andmetformin treatment; D1, first
dimension of theMFM, referring to transfer and standing posture; D2, second dimension
of theMFM, referring to proximal and axial motor functions; D3, third dimension of the
MFM, referring to distal motor function; FF, fat fraction; MFM, Motor Function Measure;
MRI, magnetic resonance imaging; 6-MWD, 6-minute walking distance; T2, transverse
weighted relaxation time.
a Themuscle groups evaluated were knee extensors, knee flexors, and abductors in
both legs.
b The 6-MWD at baseline represents data from the analysis of the prespecified
subgroup, which included 29 patients who were able to walk 350m ormore in 6
minutes and 18 patients who were not able to walk 350m in 6minutes; data are based
onMFMD1 subscores (P for interaction = .67).
c Corticosteroid treatment represents data from the analysis of the post hoc subgroup,
which included 33 patients who received corticosteroid treatment before
randomization and 14 patients who did not; data are based onMFMD1 subscores (P for
interaction = .20).
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Prespecified subgroup analyses indicated that 13 patients in the stable subgroup who received
combination therapy had a smaller, statistically significant decrease in their MFM D1 subscores after
26 weeks compared with 16 patients in the stable subgroup who received placebo (the mean
between-group difference in MFMD1 subscores was 6.7%; 95% CI, 0.9%-12.6%; P = .03); there was
no significant difference in MFMD1 subscores between patients in the unstable subgroup who
received combination therapy vs those who received placebo (3.9%; 95%, CI −13.2% to 20.9%;
P = .63; P for interaction = .67; Table 2). Post hoc subgroup analyses revealed no significant
difference in the primary outcome between patients who did and patients who did not receive
corticosteroid treatment before randomization (14.8%; 95% CI, −2.3% to 32.0%; P = .08; P for
interaction = .20 for the group that did not receive corticosteroid treatment; Table 2).
Figure 2. Effect Sizes for Primary End Point and Selected Secondary End Points
–20 1050 20–10 –5 15
Between-Group Difference (95% CI)
–15
Favors Placebo Favors Cit/MetPrimary End Point
All patients
Patients with 6-MWD ≥350 m
Effect Size, % (95% CI)
5.54 (–0.99 to 12.06)
6.74 (0.87 to 12.61)
3.89 (–13.20 to 20.98)
14.85 (–2.20 to 31.90)
2.43 (–5.68 to 10.54)
Patients with 6-MWD <350 m
Patients with corticosteroid treatment
Patients without corticosteroid treatment
Motor function based on MFM D1 subscoresA
–20 1050 20–10 –5 15
Between-Group Difference (95% CI)
–15
Favors Placebo Favors Cit/MetSecondary End Point
MFM total score
MFM D2 subscore
Effect Size, % (95% CI)
1.33 (–0.55 to 3.22)
3.12 (–0.30 to 6.55)
0.85 (–2.45 to 4.15)
11.14 (–7.36 to 29.64)
–0.24 (–45.10 to 44.62)
0.84 (–0.61 to 2.28)a
1.71 (–4.30 to 7.73)a
1.68 (0.05 to 3.30)a
1.40 (0.28 to 2.52)a
MFM D3 subscore
Strength, N
6-MWD, m
10-m walk test, s
Supine uptime, s
FF of muscle groups, %
T2 of muscle groups, ms
Muscle function, timed function, and qMRI muscle forceB
–0.75 0.250 0.75–0.25 0.50
Between-Group Difference on Normalized Scale (95% CI)
–0.50
Favors Placebo Favors Cit/MetSecondary End Point
L-lactate dehydrogenase, U/L
Gamma-glutamyl transferase, U/L
Effect Size, % (95% CI)
0.10 (–0.06 to 0.26)a
0.35 (–0.24 to 0.93)a
–0.00 (–0.09 to 0.08)a
0.03 (–0.00 to 0.06)a
0.03 (–0.05 to 0.12)
0.06 (–0.11 to 0.23)a
0.04 (–0.02 to 0.10)a
0.27 (–0.04 to 0.59)a
0.10 (–0.03 to 0.24)a
0.11 (–0.02 to 0.24)a
Bilirubin, μmol/L
Alkaline phosphatase, U/L
Creatinine, μmol/L
Summated BCAA, mmol/mol
Summated EAA, mmol/mol
Summated NEAA, mmol/mol
Summated all AA, mmol/mol
Summated BCAA and EAA, mmol/mol
Biomarkers of muscle necrosis with between-group difference on –0.75 to 0.75 normalized scaleD
–25 151050 25–15 –10 –5 20
Between-Group Difference on Normalized Scale (95% CI)
–20
Favors Placebo Favors Cit/MetSecondary End Point
Creatine kinase, U/L
Creatine-kinase-MB isoform, μg/L
Effect Size, % (95% CI)
8.51 (–5.87 to 22.89)a
8.03 (–6.76 to 22.82)a
2.55 (–0.51 to 5.61)a
2.49 (–1.86 to 6.85)a
Aspartate aminotransferase, U/L
Alanine aminotransferase, U/L
Biomarkers of muscle necrosis with between-group difference on –25 to 25 normalized scaleC
In end points for which a decrease indicated an
improvement of a test result, a sign reversal was
performed to allow comparison. AA indicates amino
acids; BCAA, branch chain amino acids; Cit/Met,
citrulline andmetformin combination therapy; D1, first
dimension of theMFM, referring to transfer and
standing posture; EAA, essential amino acids; FF, fat
fraction; MFM, Motor Function Measure; NEAA,
nonessential amino acids; qMRI, quantitative magnetic
resonance imaging; 6-MWD, 6-minute walking
distance; and T2, transverse weighted relaxation time.
JAMANetworkOpen | Neurology Effect of L-Citrulline andMetformin onMotor Function in Patients With DuchenneMuscular Dystrophy
JAMA Network Open. 2019;2(10):e1914171. doi:10.1001/jamanetworkopen.2019.14171 (Reprinted) October 30, 2019 8/14
Downloaded From: https://jamanetwork.com/ by a University of Tasmania User  on 11/03/2019
There was no indication of relevant harm associated with combination therapy, which was well
tolerated overall (Table 3). Among 17 of 23 patients (73.9%) in the treatment group and 13 of 24
patients (54.1%) in the control group, at least 1 AE was reported (relative risk, 1.4; 95% CI, 0.9-2.1).
Most AEs were of mild intensity, and the most common AEs were the occurrence of mild, transient
gastrointestinal symptoms, which are a known AE of metformin treatment that was observed in 4
patients (17.4%) who received combination therapy and 2 patients (8.3%) who received placebo
(relative risk, 2.1; 95% CI, 0.4-10.3). Severe AEs occurred in 3 patients (13.0%) who received
combination therapy and in no patients who received placebo (risk difference, 0.1; 95% CI, −0.1 to
0.3). The 3 severe AEs, which occurred exclusively in the treatment group, included 1 patient who
sustained a deep cut in his leg from glass, 1 who sustained a tibia fracture, and 1 who sustained a
femur fracture. Both of the bone fractures were caused by falls (1 patient had been treated with
corticosteroids and the other was corticosteroid-naive). Laboratory assessments of safety did not
indicate any significant changes.
All sensitivity analyses of the complete-case population and the last observation carried forward
supported the results from the ITT analyses (complete cases are described in eTable 4 in
Supplement 2). There were no relevant differences between themain analysis and the sensitivity
analysis.
Table 3. Adverse Events by Study Group
Adverse Event
No. (%)
Combination Therapy Group (n = 23) Placebo Group (n = 24)
≥1 Event 17 (73.9) 13 (54.1)
Mild or moderate
Gastrointestinal symptoms 4 (17.4) 2 (8.3)
Exanthema 2 (8.7) 3 (12.5)
Fall with contusion of the leg 2 (8.7) 1 (4.2)
Common cold 1 (4.3) 2 (8.3)
Vomiting 0 (0) 2 (8.3)
Swollen pharyngeal tonsils 2 (8.7) 0
Nausea 1 (4.3) 1 (4.2)
Mycosis 1 (4.3) 1 (4.2)
Flatulence 0 2 (8.3)
Distortion of the upper ankle joint 1 (4.3) 0
Fever 0 1 (4.2)
Cough 0 1 (4.2)
Inflammation of the middle ear 0 1 (4.2)
Vertigo 1 (4.3) 0
Loss of appetite 1 (4.3) 0
Epistaxis 0 1 (4.2)
Bug bite 1 (4.3) 0
Back pain 1 (4.3) 0
Severe
Bone fracture (tibia/femur) 2 (8.7) 0
Deep cut in the leg 1 (4.3) 0
Fatal 0 0
Discontinuation of treatment
Abnormal laboratory value 0 0
Other 0 0
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Discussion
The treatment of patients with DMD remains an unmet medical need. Recent therapeutic advances
that target specific mutations strongly limit the number of patients who are able to benefit from
these treatment options.31,32 To explore a newmutation-independent therapy, we investigated the
efficacy and safety of treatment with a combination therapy in ambulant patients with DMD.
Although we detected a clinically relevant mean between-group difference of 5.5%
(corresponding to a 58% reduction in transfer and standingmotor function decline) at 26 weeks in
favor of patients treated with combination therapy, this study did not demonstrate a statistically
significant treatment benefit. The clinical variability among the participants was larger than we
assumed in our sample size estimation; therefore, a larger variability across individual treatment
effects was observed. One reason for this uncalculated variability was the improvement of muscle
function observed among some young patients (aged 6.5-8 years at baseline) in the unstable
subgroup who received placebo. These patients continued to gain muscle function during the study
period owing to normalmotor development, which resulted in higher interindividual variability and
lower statistical significance. In contrast, in the predefined stable subgroup of patients with a
baseline 6-MWD of 350m ormore, a very low variability with a steadymuscle function decline was
observed among those receiving placebo. In this subgroup, a clinically meaningful and significant
reduction of theMFMD1 subscore decrease of 6.7%was observed in patients treated with
combination therapy compared with placebo. Furthermore, in the overall population and the stable
subgroup, key secondary clinical end points, including MFM total scores, quantitative muscle force
assessments, 10-m walk tests, and supine uptimes at weeks 13 and 26, were consistently in favor of
the combination therapy group compared with the placebo control group (Figure 2).
Laboratory end points related tomuscle necrosis were also consistently better among patients
treated with combination therapy (Figure 2). A significant reduction of nonessential amino acids in
the urine of patients receiving combination therapy compared with those receiving placebo
represents a reduced loss of amino acids in the urine, which is indicative of reducedmuscle
degeneration. TheMRI findings were of special interest for our study. The decrease in muscle
degenerationmeasured by qMRI muscle sequences was significantly in favor of the treatment group
compared with the control group. These results highlight a meaningful reduced transformation of
normal muscle into fatty tissue by 66% in the treatment group compared with 58% in the control
group. To our knowledge, combination therapy is the first to show a significant slowing in muscle
degeneration based on an analysis of qMRI results in a randomized placebo-controlled clinical trial.
Because corticosteroids slow muscle degeneration, as assessed by qMRI,33 patients with DMD who
were treated with corticosteroids demonstrated a smaller increase in FF after 1 year of treatment
compared with age-matched patients who were not treated with corticosteroids. However, in
contrast to the results of our study treatment, no significant differences in FF were detectable after
3 and 6months of corticosteroid treatment.33
Overall, the significant differences in theMFMD1 subscores of the larger andmore
homogeneous stable subgroup, the increasing differences between the treatment and control
groups over time, the significant findings from the qMRI examinations, and the consistent results
from the clinical and laboratory end points are supportive of combination therapy for the treatment
of patients with DMD; however, these findings also indicate that this studymay have lacked sufficient
statistical power. The reasons for this lack of power may include the fact that the sample size
calculations were based on data from a pilot study of only 5 patients,18 andmotor function
improvements among the young, still-developing patients in the control group were not considered.
Furthermore, we were surprised to detect altered baseline NO-related amino acid plasma
concentrations, which suggest that DMDmay be associated with an increased L-citrulline
metabolism in patients. A total of 36% of patients had L-citrulline values below the lower limits of
normal (defined as 18-50 μmol/L), and 76%of patients had L-ornithine plasma levels above the upper
limit of normal (defined as 24-64 μmol/L). This observation provides further indication that a
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possible NO-related amino acid disturbancemay be associated with muscle dysfunction in patients
with DMD.
In this study, treatment with combination therapy was safe and well tolerated. Themost
common AEwas the occurrence of mild, transient gastrointestinal symptoms, which is a known AE
of metformin treatment. Severe AEs occurred in only 3 patients in the treatment group; 2 of those
were bone fractures, which are common complications in patients with DMD, indicating that an
association with the combination therapy is unlikely.
Limitations
This study was limited by a short observation period of 26 weeks. Other limitations included a small
patient sample and the unknown contributions of each individual substance (L-citrulline and
metformin) to the observed effects.
Conclusions
This study found that treatment with combination therapy was not associated with an overall
reduction in motor function decline among ambulant patients with DMD; however, a reduction in
motor function decline was observed among the stable subgroup of patients treated with
combination therapy. Combination therapy has a better safety profile than corticosteroid treatment
and is suitable for any patient with DMD,whatever his genetic condition; thus, the administration of
combination therapy represents a promising treatment option to ameliorate muscular metabolism
and reduce clinical decline in patients with DMD. A larger and longer multicenter study is planned to
evaluatewhether treatmentwith combination therapy is associatedwith a delay in the progression
of DMD.
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